Pharmacy Practice Faculty Publications

Recent publications

• Early vs. Delayed Initiation of Treatment With P2Y₁₂ Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials May 16, 2022
  CONCLUSION: In patients with NSTE-ACS, delayed prasugrel initiation was the most effective strategy to reduce MACE. Although early prasugrel was the best option to reduce most secondary cardiovascular outcomes, it was associated with the highest bleeding risk. The opposite was found for delayed clopidogrel.
  Lourdes Vicent
• Activating P2Y₁ receptors improves function in arteries with repressed autophagy May 13, 2022
  CONCLUSIONS: Arterial dysfunction concurrent with pharmacological, genetic, and age-associated EC autophagy disruption is improved by activating P2Y(1) -Rs.
  Jae Min Cho
• Criminal Action Against Drug Counterfeiters: Assessment of the FDA Office of Criminal Investigation Database 2016 Through 2021 May 3, 2022
  CONCLUSION AND RELEVANCE: This is the first report assessing enforcement actions against drug counterfeiters from the FDA Office of Criminal Investigation. The FDA is actively involved in identifying and prosecuting counterfeit drug rings, but the number of enforcement actions is smaller than the size of the problem.
  C Michael White
• Activating P2Y1 receptors improves function in arteries with repressed autophagy April 14, 2022
  CONCLUSIONS: Arterial dysfunction concurrent with pharmacological, genetic, and age-associated EC autophagy compromise is improved by activating P2Y1-Rs.
  Jae Min Cho
• Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study April 8, 2022
  CONCLUSIONS: Rivaroxaban 15 mg may be associated with a lower risk of worsening kidney function as compared with warfarin in the atrial fibrillation population with moderate-to-severe CKD.
  Tatsiana Vaitsiakhovich
• Gender Differences in Depressive and Anxiety Symptoms During the First Stage of the COVID-19 Pandemic: A Cross-Sectional Study in Latin America and the Caribbean April 4, 2022
  CONCLUSION: Approximately 4 out of 10 participants had anxiety or depressive symptoms. Women and non-binary gender people had more symptoms of anxiety or depression. The factors associated with these symptoms varied according to gender. It is essential to evaluate gender-related strategies to improve mental health during the COVID-19 pandemic.
  Percy Herrera-Añazco
• Continued Risk of Dietary Supplements Adulterated With Approved and Unapproved Drugs: Assessment of the US Food and Drug Administration's Tainted Supplements Database 2007 Through 2021 March 14, 2022
  The US Food and Drug Administration created the Tainted Dietary Supplement Database in 2007 to identify dietary supplements adulterated with active pharmaceutical ingredients (APIs). This article compares the determination of API adulteration in dietary supplements from the 10-year time period of 2007 through 2016 to the most recent 5-year period of 2017 through 2021. From […]
  C Michael White
• Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction March 13, 2022
  Inclisiran increases the number of low-density lipoprotein surface receptors expressed on hepatocytes using small interfering RNA directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA. This novel mechanism can reduce low-density lipoprotein by ≈50%, like reductions achieved with high-intensity statins or PCSK9-inhibiting monoclonal antibodies. Inclisiran is indicated in the treatment of adults with heterozygous familial […]
  Kimberly W Smith
• Linagliptin-Induced Arthralgia February 28, 2022
  No abstract
  Stefanie C Nigro
• Contemporary Treatment of Resistant Gram-Negative Infections in Pediatric Patients February 16, 2022
  Gram-negative resistance is increasing in serious infections, including in children. There are many mechanisms of resistance, most commonly beta-lactamases. The most concerning beta-lactamases are AmpC, extended spectrum beta-lactamases, and carbapenemases. Efflux pumps and porins are also important in Pseudomonas infections. For some mechanisms of resistance, dose adjustment of antibiotics may help to overcome resistance and […]
  Samantha A Basco
• Prevalence of statin intolerance: a meta-analysis February 16, 2022
  CONCLUSION: Based on the present analysis of >4 million patients, the prevalence of SI is low when diagnosed according to international definitions. These results support the concept that the prevalence of complete SI might often be overestimated and highlight the need for the careful assessment of patients with potential symptoms related to SI.
  Ibadete Bytyçi
• A systematic review and meta-analysis of randomized controlled trials evaluating pharmacologic therapies for acute and recurrent pericarditis February 8, 2022
  Acute idiopathic pericarditis (AIP) is a benign inflammatory condition associated with high recurrence rates. Non-steroidal anti-inflammatory drug (NSAIDs) and colchicine are the recommended therapies. Our objective was to systematically assess effects of pharmacological therapies on recurrences or treatment failure in patients with first and subsequent AIP episodes. PubMed, BioMedCentral, Cochrane, Clinicaltrials.gov, Google Scholar and EMBASE […]
  Maria Melendo-Viu
• Pharmacists Have the Stats but No Provider Status: Now May Be Our Moment February 2, 2022
  No abstract
  C Michael White
• Risk factors for drug therapy problems among Cambodian Americans with complex needs: a cross-sectional, observational study January 28, 2022
  CONCLUSIONS: Vulnerable patients should be prioritized for pharmacist/CHW teams to identify DTPs.Trial registration: ClinicalTrials.gov identifier: NCT02502929.
  Julie A Wagner
• Finerenone: A Novel Mineralocorticoid Receptor Antagonist for Cardiorenal Protection in CKD and T2DM January 13, 2022
  CONCLUSIONS: Finerenone offers a unique approach to further delay the progression of chronic kidney disease in patients with type 2 diabetes mellitus. It also provides another option for patients who cannot tolerate RASi or sodium-glucose cotransporter-2 inhibitors.
  Allissa Long